Table 4.
Phenotype of leukemic stem cells (LSC) and identified targetsa
| Disease/neoplasm | Primary phenotype | Molecular targetsa |
|---|---|---|
| AML (CD34+)b | CD34+/CD38−; CD34+/CD38+ | CD33, CD44, CD52, KIT, |
| CD34+/CD38−/CD123+ | FLT3, HO-1, BRD4, MYC | |
| CD34+/CD38−/CD25+ | ||
| CD34+/CD38−/CLL-1+ | ||
| Ph+ CML | CD34+/CD38−/CD25+/CD26+/ | CD33, CD44, CD52, KIT, |
| CD56+/CD93+/L-1RAP+ | HO-1, MCL-1, AURKA/B | |
| Ph+ ALL | CD34+/CD38−; CD34+/CD38+ | CD19, CD22, CD33, CD52 |
| CD34+/CD38−/CD25+/CD26+ | HO-1, BLC-2, MCL-2 | |
| Ph− ALL | CD34+/CD38−; CD34+/CD38+ | CD19, CD22, CD33, CD52 |
| CD34+/CD38−/CD25+ | HO-1, BCL-2, MLC-1 | |
| CLL | CD34+/CD19+/CD5+ | CD20, CD23, CD44, CD52 |
| Notch1/2, PTEN, PI3K | ||
| ASM/MCL | CD34+/CD38−/CD123+ | CD33, CD44, CD52, KIT |
| HO-1, FES, AURKA/B, |
Cell surface expression of markers and targets on LSC was determined by multi-color flow cytometry
AML acute myeloid leukemia, HO-1 heme oxygenase-1, CML chronic myeloid leukemia, ALL acute lymphoblastic leukemia, CLL chronic lymphocytic leukemia, PI3K phosphoinositide-3-kinase, ASM aggressive systemic mastocytosis, MCL mast cell leukemia, AURK aurora kinase
aThe Table includes a few selected molecular targets identified in LSC by members of the LBC ONC in the past 10 years
bIn AML, both the CD34+/CD38− and CD34+/CD38+ subsets of CD34+ cells contain LSC